<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357653</url>
  </required_header>
  <id_info>
    <org_study_id>BEST-IGAN-001</org_study_id>
    <nct_id>NCT03357653</nct_id>
  </id_info>
  <brief_title>Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1</brief_title>
  <acronym>BEST-IgAN-1</acronym>
  <official_title>A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health Insurance Service Ilsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangdong Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ewha Womans University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. IgAN is
      progressive, particularly when patients have a significant proteinuria (proteinuria &gt;1g/g
      creatinine), impaired kidney function, or elevated blood pressure. In 10 years, nearly 20-40%
      of these IgAN patients progress to end-stage renal disease (ESRD). Early IgAN is tentatively
      defined when proteinuria is insignificant and kidney function and blood pressure are normal.
      Patients with early IgAN rarely progress to ESRD. However, 30-40% of patients with early IgAN
      ultimately developed a significant proteinuria and hypertension in 10 years. Therefore,
      earlier intervention may be needed if it can prevent the development of a significant
      proteinuria and hypertension. Since angiotensin ll receptor blocker (ARB) is drug of choice
      in reducing proteinuria and controlling blood pressure, the investigators hypothesized that
      early introduction of ARB may be beneficial in preventing the significant proteinuria
      development in early IgAN patients. To prove the hypothesis, the investigators plan the
      current interventional study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The investigators will test the effect of ARB to prevent the development of significant proteinuria, defined as random urine protein-to-creatinine ratio of &gt;1g/g creatinine. In this study, the investigators choose losartan as a testing ARB. The investigators will compare the rate of significant proteinuria development between 2 arms, namely losartan group and placebo group after 144 weeks' treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant proteinuria rate</measure>
    <time_frame>144 weeks after study started</time_frame>
    <description>Random urine protein-to-creatinine ratio &gt;= 1g/g creatinine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proteinuria remission rate</measure>
    <time_frame>48 weeks, 96 weeks, and 144 weeks after study started</time_frame>
    <description>Random urine protein-to-creatinine ratio &lt; 0.20 g/g creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impaired kidney function rate</measure>
    <time_frame>48 weeks, 96 weeks, and 144 weeks after study started</time_frame>
    <description>estimated glomerular filtration rate decline &gt;= 40% from the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension development rate</measure>
    <time_frame>48 weeks, 96 weeks, and 144 weeks after study started</time_frame>
    <description>Systolic blood pressure &gt;= 140 or diastolic blood pressure &gt;= 90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Glomerulonephritis, Immunoglobulin A (IgA)</condition>
  <arm_group>
    <arm_group_label>Losartan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 50 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 pill daily which has same size, color and taste with losartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan group</intervention_name>
    <description>Losartan 50 mg daily</description>
    <arm_group_label>Losartan group</arm_group_label>
    <other_name>Losartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Placebo 1 pill daily</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biopsy-proven IgAN: dominant or co-dominant deposits of mesangial IgA in
             immunofluorescence stain

          2. Age &gt;= 19 years

          3. Random urine protein-to-creatinine ratio 0.3 g/g creatinine to 1.0 g/g creatinine at
             visit 1

          4. Estimated glomerular filtration rate &gt;= 60 mL/min/1.73m2 at visit 1

          5. People who voluntarily agreed to participate

          6. People who are compliant

        Exclusion Criteria:

          1. Prevalent Hypertension: systolic blood pressure &gt;=140 mmHg and &gt;=90 mmHg, previous
             physician diagnosis of hypertension, or taking anti-hypertensive drugs

          2. Prevalent Diabetes: fasting glucose &gt;= 126 mg/dL, HbA1c &gt;= 6.5%, taking insulin or
             anti-diabetic drugs, or previous physician diagnosis of diabetes

          3. Previous immunosuppressive drugs use to treat IgAN

          4. Secondary IgAN

          5. Renin-angiotensin-aldosterone inhibitors (RASI) dependent patients (congestive heart
             failure, ischemic heart disease, and others)

          6. hypersensitivity to RASI

          7. Other chronic diseases: malignancy within 5 years, significant liver and
             gastrointestinal disease and other autoimmune disease

          8. Pregnancy

          9. symptomatic orthostatic hypotension

         10. People who already participated in other interventional studies or taking
             interventional drugs within 3 month of screening visit

         11. Inappropriate people ascertained by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Ryeol Ryu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Ryeol Ryu, Professor</last_name>
    <phone>82-2-2650-2507</phone>
    <email>drryu@ewha.ac.kr</email>
  </overall_contact>
  <reference>
    <citation>Li PK, Kwan BC, Chow KM, Leung CB, Szeto CC. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Am J Med. 2013 Feb;126(2):162-8. doi: 10.1016/j.amjmed.2012.06.028.</citation>
    <PMID>23331443</PMID>
  </reference>
  <reference>
    <citation>Jo YI, Na HY, Moon JY, Han SW, Yang DH, Lee SH, Park HC, Choi HY, Lim SD, Kie JH, Lee YK, Shin SK. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial. Korean J Intern Med. 2016 Mar;31(2):335-43. doi: 10.3904/kjim.2014.266. Epub 2016 Feb 15.</citation>
    <PMID>26874511</PMID>
  </reference>
  <reference>
    <citation>Nieuwhof C, Kruytzer M, Frederiks P, van Breda Vriesman PJ. Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy. Am J Kidney Dis. 1998 Jun;31(6):962-70.</citation>
    <PMID>9631840</PMID>
  </reference>
  <reference>
    <citation>Lai FM, Szeto CC, Choi PC, Li PK, Chan AW, Tang NL, Lui SF, Wang AY, To KF. Characterization of early IgA nephropathy. Am J Kidney Dis. 2000 Oct;36(4):703-8.</citation>
    <PMID>11007671</PMID>
  </reference>
  <reference>
    <citation>Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, Lui SF, Li PK. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001 Apr 15;110(6):434-7.</citation>
    <PMID>11331053</PMID>
  </reference>
  <reference>
    <citation>Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106(4):c157-61. Epub 2007 Jun 26.</citation>
    <PMID>17596724</PMID>
  </reference>
  <reference>
    <citation>Lee H, Hwang JH, Paik JH, Ryu HJ, Kim DK, Chin HJ, Oh YK, Joo KW, Lim CS, Kim YS, Lee JP. Long-term prognosis of clinically early IgA nephropathy is not always favorable. BMC Nephrol. 2014 Jun 19;15:94. doi: 10.1186/1471-2369-15-94.</citation>
    <PMID>24946688</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>proteinuria</keyword>
  <keyword>progression</keyword>
  <keyword>early immunoglobulin A (IgA) nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

